A study conducted by Lebedev et al. in 2020 that investigated the profile of variate biomarkers (NT-pro BNP, galectin-3, ST2, MMP-9, hs-CRP, PIIINP, TIMP-1) in 62 patients with diabetes and obesity and chronic stable HF with preserved and midrange EF (in the NYHA II functional class and optimal HF drug therapy for a minimum of 3 months) and diabetic patients without HF. This evidence concerns the gene LGALS3 and obesity disorder.